Stephen V. Frye

Stephen V. Frye

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
WZWeihe Zhang
Weihe Zhang
DDDeborah DeRyckere
Deborah DeRyckere
DHDebra Hunter
Debra Hunter
JLJing Liu
Jing Liu
MSMichael A. Stashko
Michael A. Stashko
XWXiaodong Wang
Xiaodong Wang
We previously reported a potent small molecule Mer tyrosine kinase inhibitor UNC1062. However, its poor PK properties prevented further assessment in vivo. We report here the sequential modification of UNC1062 to address DMPK properties and yield a new potent and highly orally bioavailable Mer inhibitor, 11, capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examining phospho-Mer in leukemic blasts from mouse bone marrow. Kinome profiling versus more than 300 kinases in vitro and cellular selectivity assessments demonstrate that 11 has similar subnanomolar activity against Flt3, an additional important target in acute myelogenous leukemia (AML), with pharmacologically useful selectivity versus other kinases examined.

6 January 2013 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
LJLindsey I James
Lindsey I James
DBDalia Barsyte-Lovejoy
Dalia Barsyte-Lovejoy
NZNan Zhong
Nan Zhong
LKLiubov Krichevsky
Liubov Krichevsky
VKVictoria K Korboukh
Victoria K Korboukh
SFStephen V. Frye
Stephen V. Frye
Methylation of lysine residues regulates chromatin function in part by recruiting readers to these marks. UNC1215, a selective antagonist of the methyllysine reader L3MBTL3 with a polyvalent mode of interaction, reveals BCLAF1 as a methyllysine-dependent interaction partner for L3MBTL3. We describe the discovery of UNC1215, a potent and selective chemical probe for the methyllysine (Kme) reading function of L3MBTL3, a member of the malignant brain tumor (MBT) family of chromatin-interacting transcriptional repressors. UNC1215 binds L3MBTL3 with a Kd of 120 nM, competitively displacing mono- or dimethyllysine-containing peptides, and is greater than 50-fold more potent toward L3MBTL3 than other members of the MBT family while also demonstrating selectivity against more than 200 other reader domains examined. X-ray crystallography identified a unique 2:2 polyvalent mode of interaction between UNC1215 and L3MBTL3. In cells, UNC1215 is nontoxic and directly binds L3MBTL3 via the Kme-binding pocket of the MBT domains. UNC1215 increases the cellular mobility of GFP-L3MBTL3 fusion proteins, and point mutants that disrupt the Kme-binding function of GFP-L3MBTL3 phenocopy the effects of UNC1215 on localization. Finally, UNC1215 was used to reveal a new Kme-dependent interaction of L3MBTL3 with BCLAF1, a protein implicated in DNA damage repair and apoptosis.

1 October 2019 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
AHAlisha Holtzhausen
Alisha Holtzhausen
WHWilliam Harris
William Harris
EUEric Ubil
Eric Ubil
DHDebra M. Hunter
Debra M. Hunter
JZJichen Zhao
Jichen Zhao
HEH. Shelton Earp
H. Shelton Earp
Myeloid cell receptor tyrosine kinases TYRO3, AXL, and MERTK and their ligands, GAS6 and PROTEIN S, physiologically suppress innate immune responses, including in the tumor microenvironment. Here, we showed that myeloid-derived suppressor cells (MDSC) dramatically upregulated TYRO3, AXL, and MERTK and their ligands [monocytic MDSCs (M-MDSC)>20-fold, polymorphonuclear MDSCs (PMN-MDSC)>15-fold] in tumor-bearing mice. MDSCs from tumor-bearing Mertk−/−, Axl−/−, and Tyro3−/− mice exhibited diminished suppressive enzymatic capabilities, displayed deficits in T-cell suppression, and migrated poorly to tumor-draining lymph nodes. In coimplantation experiments using TYRO3−/−, AXL−/−, and MERTK−/− MDSCs, we showed the absence of these RTKs reversed the protumorigenic properties of MDSCs in vivo. Consistent with these findings, in vivo pharmacologic TYRO3, AXL, and MERTK inhibition diminished MDSC suppressive capability, slowed tumor growth, increased CD8+ T-cell infiltration, and augmented anti–PD-1 checkpoint inhibitor immunotherapy. Mechanistically, MERTK regulated MDSC suppression and differentiation in part through regulation of STAT3 serine phosphorylation and nuclear localization. Analysis of metastatic melanoma patients demonstrated an enrichment of circulating MERTK+ and TYRO3+ M-MDSCs, PMN-MDSCs, and early-stage MDSCs (e-MDSC) relative to these MDSC populations in healthy controls. These studies demonstrated that TYRO3, AXL, and MERTK control MDSC functionality and serve as promising pharmacologic targets for regulating MDSC-mediated immune suppression in cancer patients.

18 March 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JHJ. Martin Herold
J. Martin Herold
TWTim J. Wigle
Tim J. Wigle
JNJacqueline L. Norris
Jacqueline L. Norris
RLRobert Lam
Robert Lam
VKVictoria K. Korboukh
Victoria K. Korboukh
SFStephen V. Frye
Stephen V. Frye

1 June 2011 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
SFStephen V. Frye
Stephen V. Frye
MCMarina Crosby
Marina Crosby
TETeresa Edwards
Teresa Edwards
RJRudolph L. Juliano
Rudolph L. Juliano

17 December 2019 in ACS Chemical Biology
Verified
Journal Article
Closed access
CFCaroline A. Foley
Caroline A. Foley
FPFrances Potjewyd
Frances Potjewyd
KLKelsey N. Lamb
Kelsey N. Lamb
LJLindsey I. James
Lindsey I. James
SFStephen V. Frye
Stephen V. Frye